105
Participants
Start Date
September 15, 2017
Primary Completion Date
October 13, 2023
Study Completion Date
February 6, 2024
Nivolumab
480mg
Nivolumab
240mg
Ipilimumab
1mg/kg
Penn State Cancer Institute, Hershey
Johns Hopkins Sidney Kimmel Comprehensive, Baltimore
University of Louisville James Graham Brown Cancer Center, Louisville
Indiana University, Indianapolis
Karmanos Cancer Center (Wayne State University), Detroit
Michigan State University, Lansing
University of Wisconsin, Madison
University of Minnesota, Minneapolis
Rush University Medical Center, Chicago
University of Illinois Cancer Center, Chicago
University of Nebraska Medical Center, Omaha
Rutgers Cancer Institute of New Jersey, New Brunswick
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Big Ten Cancer Research Consortium
OTHER
Greg Durm, MD
OTHER